• Overactive bladder (OAB), including urge urinary incontinence, urgency, and frequency (either as monotherapy or in combination with solifenacin).
• Pediatric neurogenic detrusor overactivity.

Contraindicated in:

• Hypersensitivity
• Severe uncontrolled hypertension
• End-stage renal disease (eGFR <15 mL/min/1.73 m² or requiring dialysis)
• Severe hepatic impairment.

Use Cautiously in:

• Hypertension
• Bladder outlet obstruction/concurrent antimuscarinics (↑ risk of urinary retention)
• Concurrent use of antimuscarinics used to treat OAB
• OB: Safety not established in pregnancy
• Lactation: Safety not established in breastfeeding
• Pedi: Children <3 yr (safety and effectiveness not established).

CV: ↑ BP, tachycardia.

EENT: nasopharyngitis.

GI: constipation, diarrhea, nausea.

GU: urinary tract infection.

Neuro: dizziness, headache.
Misc: ANGIOEDEMA.

Drug-Drug:

• May ↑ levels and risk of toxicity of CYP2D6 substrates, including desipramine, flecainide, metoprolol, propafenone, and thioridazine.
• May ↑ levels and risk of toxicity with digoxin; use lowest effective level of digoxin/monitor serum levels).

(Generic available)

• Extended-release tablets: 25 mg; 50 mg;
• Extended-release oral suspension (granules): 8 mg/mL;

Overactive Bladder

• PO (Adults): 25 mg once daily; may ↑ to 50 mg once daily, if needed, after 4–8 wk.

Neurogenic Detrusor Overactivity

• PO (Children ≥3 yr and ≥35 kg): Extended-release tablets: 25 mg once daily; may ↑ to 50 mg once daily, if needed, after 4–8 wk. Extended-release oral suspension (granules): 48 mg once daily; may ↑ to 80 mg once daily, if needed after 4–8 wk.
• PO (Children ≥3 yr and 22–<35 kg): Extended-release oral suspension (granules): 32 mg once daily; may ↑ to 64 mg once daily, if needed after 4–8 wk.
• PO (Children ≥3 yr and 11–<22 kg): Extended-release oral suspension (granules): 24 mg once daily; may ↑ to 48 mg once daily, if needed after 4–8 wk.

Myrbetriq

• Acts as a selective beta-3 adrenergic agonist.
• Increases bladder capacity by relaxing detrusor smooth muscle during storage phase of bladder fill-void cycle.

• Decreased symptoms of OAB.
• Improved bladder capacity in neurogenic detrusor overactivity.

Therapeutic Classification: urinary tract antispasmodics

Pharmacologic Classification: beta-adrenergic agonists

Absorption: 29–35% absorbed following oral administration.

Distribution: Widely distributed.

Metabolism/Excretion: Extensively metabolized, 6% excreted unchanged in urine (25 mg dose), remainder excreted in urine and feces as metabolites.

Half-life: Adults: 50 hr; Children: 26–31 hr.

(effects on bladder)

†Blood level.

• Instruct patient to take mirabegron as directed. If a dose is missed, take as soon as remembered unless >12 hrs since missed dose. If >12 hrs since missed dose, omit dose and take next dose at scheduled time. Advise patient to read Patient Information sheet prior to starting and with each Rx refill, in case of changes.
• Inform patient that mirabegron may cause an increase in BP. Advise patient to have BP checked periodically during therapy.
• May cause dizziness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
• Advise patient to notify health care professional if difficulty emptying bladder occurs.
• Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
• Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

mye-ra-BEG-ron